Navigation Links
Allegheny General Hospital Launches Study to Determine Best Practices for Treating Epilepsy in the Emergency Room
Date:8/12/2015

Allegheny General Hospital, part of the Allegheny Health Network, is one of 39 medical centers across the United States participating in a clinical trial to help determine better ways to treat patients with prolonged seizures in Emergency Departments.

Currently, there is not a standardized protocol for emergency treatment of Status Epilepticus (SE), a seizure or recurrent seizures lasting longer than five minutes without stopping or waking up. A person whose seizure doesn’t stop after receiving a full dose of medicine designed to stop seizures is considered to have Established Status Epilepticus (ESE).

The Established Status Epilepticus Treatment Trial (ESETT) will study three commonly used medicines given in the Emergency Department for ESE, phenoytoin, valproic acid and levetiracetam, to determine which of these is safest and most effective.

“Physicians use their best judgment to treat seizures in an emergency setting, but there currently is no substantial clinical evidence to show that one medication stands out above the rest,” said Andrea Synowiec, DO, principal investigator of the study at Allegheny General.

“The data that we collect in the ESETT Trial will enable physicians to determine best practices and create a standard protocol for emergency treatment of ESE that will yield the best possible outcomes for patients, no matter where they are treated.”

Prolonged seizures can happen to people of any age, affecting the ability to think and remember, function normally and live independently. In serious cases, SE may limit awareness or cause coma, permanent brain damage or death. There are approximately 120,000 to 180,000 episodes of SE each year in the United States.

The ESETT trial will involve any patient 2 years or older with an active recurrent or ongoing seizure lasting longer than five minutes which fails to respond to a full dose of medication that should stop it. Patients will randomly receive one of the three study medications and blood samples may be taken. If the seizure does not stop, physicians will give extra medication, which could be one of the three study drugs or a different medication.

Because a person having a seizure is unable to provide consent to participate in research and the requirement of timely treatment makes it impossible to get consent from the patient’s family, patients will be enrolled without consent. This Exception from Informed Consent is lifted once the patient wakes up or his or her legal representative is located and the study team can inform them about the trial and request permission to continue in the study.

The ESETT study is part of the Neurological Emergencies Treatment Trials and Pediatric Emergency Care & Applied Research Network, which are funded by the National Institutes of Health. In addition to Allegheny General Hospital, UPMC Presbyterian Hospital and Children’s Hospital of Pittsburgh will also enroll patients in the ESETT trial.
To learn more about the study, including the opportunity to decline participation, visit http://www.esett.org or call 412.359.5075.

About Allegheny General Hospital
Allegheny General Hospital’s Neuroscience Program has long been regarded as one of the nation’s leading referral centers for the treatment of brain injuries and complex neurological diseases, including epilepsy. The Comprehensive Epilepsy Program at AGH was established in 1987 and has become one of the largest such services in the tri-state area. Along with diagnostic expertise, the program offers advanced medical and surgical treatments for epilepsy. AGH is a member of the National Association of Epilepsy Centers and has earned the Association’s highest Level 4 designation.

Read the full story at http://www.prweb.com/releases/2015/08/prweb12901465.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved

Related medicine news :

1. Noted Duke Brain Cancer Specialist to Direct Allegheny Health Network Neuro-Oncology Program
2. Allegheny Health Network Research Confirms Value of Less-Invasive POEM Procedure For Wider Range of Esophageal Disorders
3. Allegheny Health Network's Susan Manzi, MD, Receives National Lupus Advocacy Award
4. Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech
5. Allegheny General Hospital Introduces New Treatment for Relapsing Multiple Sclerosis
6. Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue
7. Allegheny Health Network Transplant Team Participates in Nation’s Largest Multi-State Paired Kidney Exchange
8. Western Pennsylvania’s First Robotic-Assisted Hip and Knee Surgeries Performed at Allegheny Health Network’s West Penn Hospital
9. Nationally-Recognized Cleveland Clinic Foot and Ankle Surgeon, James J. Sferra, MD, to Lead Allegheny Health Network Program
10. Allegheny Health Network Physician Research Points to Possible New Paradigm in Ovarian Cancer Treatment
11. Allegheny General Hospital Performs Milestone Transcatheter Aortic Valve Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... Durham, NC (PRWEB) , ... March 30, 2017 ... ... professionals, will host the live audio conference “ Preventing Hospital Readmissions Through Discharge ... April 12, 2017 at 1:00 pm ET. This conference discusses strategies to prevent ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS ... Medical Center will serve as the official title sponsor of the Baltimore Women’s Classic, ... 2017, thousands of women will walk or run the course around the Baltimore Inner ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy ... attending prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. ... recognized as the visionary leader in the training of physicians, scientists, and members ...
(Date:3/29/2017)... ... 29, 2017 , ... Patients interested in receiving quick and ... Jamie Cameron, with or without a referral. The FASTBRACES system is valued for ... each patient’s case, treatment with the FASTBRACES system could be completed in 120 ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 ... "Intraoperative Neuromonitoring (IONM) Market Size & Forecast By Type (Insource ... - 2025" report to their offering. ... The global Intraoperative ... by 2025. The intraoperative neuromonitoring market is anticipated to witness ...
(Date:3/29/2017)... March 29, 2017 Global intravenous (IV) iron and ... by 2021, growing at a CAGR of 5%. ... a doctor to treat anemia or other iron deficiencies. Oral ... the body. However, in some cases, oral administrations are not ... intravenous (IV) iron therapy comes into the picture. ...
(Date:3/29/2017)... 29, 2017 Today, CVS Health officials (NYSE: ... , Department of Public Health Director Gerd Clabaugh ... in announcing the availability of the opioid overdose-reversal medicine ... Iowa.  CVS Health has established a standing order with physicians ... to expand access to the medication in the state.   ...
Breaking Medicine Technology: